Annie Talbot

Back to Profile

Publication Details

  • Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

    Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. J Clin Virol. 2009; 46 (4): 305-8

    Raltegravir is a potential treatment option for virologically suppressed HIV-1 infected patients on enfuvirtide with injection site reactions.

    PubMedID: 19819183

Stanford Medicine Resources:

Footer Links: